

## THE NOMINATION COMMITTEE APPOINTED FOR THE ANNUAL GENERAL MEETING 2025.

The nomination committee is appointed in consultation with the three largest shareholders or owner groups, according to the number of votes based on shareholder statistics from Euroclear Sweden, and other reliable owner information in accordance with the decision of the Annual General Meeting.

The nomination committee's task is to produce proposals for the AGM regarding the chairman of the meeting, the board, the chairman of the board, board fees with a division between the chairman and other members of the board, auditors and fees to auditors and, where applicable, proposals for revising the principles for the appointment of the nomination committee.

The nomination committee for the 2025 AGM in Prolight Diagnostics AB (publ.) consists of chairman Jan Karlsson, who represents his own shares, appointed in accordance with the largest shareholders by number of votes. Other members are Paul Monaghan, who represents his own shares, appointed in accordance with the number of votes of the largest shareholders. Per-Anders Josenby, who represents Cardeon AB, appointed in accordance with the number of votes of the largest shareholders.

Shareholders who wish to submit proposals to the nomination committee can do so in writing to:

“Valberedningen”  
Prolight Diagnostics AB (publ)  
Gasverksgatan 3A  
222 29 Lund  
Sweden

Or by e-mail to:

**[valberedningen@prolightdx.com](mailto:valberedningen@prolightdx.com)**

**For further information, please contact:**

Ulf Bladin, CEO

E-mail: **[info@prolightdx.com](mailto:info@prolightdx.com)**

Phone: +46 73 582 39 87

Company website: **[www.prolightdx.com](http://www.prolightdx.com)**

### About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

## **Attachments**

**The nomination committee appointed for the Annual General Meeting 2025.**